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Abstract
Background: Biological factors influencing individual response to drugs are being extensively
studied in psychiatry. Strikingly, there are few studies addressing social and cultural differences in
attitudes toward psychotropic medications. The objective of this study was to investigate ethno-
culturally determined beliefs, expectations and attitudes toward medication among a sample of
hospitalized psychiatric patients.
Methods: An ad hoc questionnaire was designed to assess patients' expectations, attitudes and
prejudice toward medication. The study included 100 adult patients hospitalized in Geneva,
Switzerland.
Results: Patients were in majority male (63%), originated from Switzerland (54%) and spoke the
local language fluently (93%). They took on the average 3 different psychotropic drugs. Sixty-eight
percent of patients expected side effects and 60% were ready to stop medication because of them.
Thirty percent of patients expected negative personal changes with treatment and 34% thought
that their mental disorder could have been treated without drugs. Thirty six percent of the sample
used alternative or complementary medicines. 35% of immigrant patients believed that medication
had different effects on them than on local patients. When compared with Swiss patients, they
more often reported that significant others had an opinion about medication (p = 0.041) and more
frequently valued information provided by other patients about treatment (p = 0.010).
Conclusion: Patients' attitudes toward medication should be investigated in clinical practice, as
specific expectations and prejudice exist. Targeted interventions, especially for immigrant patients,
might improve adherence.
Background
Biological factors determining the effects of psychotropic
medications are extensively studied for each drug cate-
gory, both from pharmacokinetic and pharmacodynamic
perspectives. The study of genetic variants influencing
drug metabolism has developed more recently, through
the emergence of pharmacogenetics [1]. This approach
might permit to draw different metabolic profiles for dif-
ferent ethnicities and races, even though its clinical use is
still limited [2,3]. More broadly, the utilization of genetic
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information to predict outcome of drug treatment, or
pharmacogenomics, holds great promise for clinical psy-
chiatry [4].
However, non-biological factors such as level of adher-
ence to medication continue to impact profoundly upon
treatment outcome [5]. Medication nonspecific therapeu-
tic and adverse effects, respectively the placebo and
nocebo phenomena, constitute important determinants
of treatment outcome [6]. Social and ethno-cultural deter-
minants of drug treatment outcome, such as patients'
expectations and attitudes toward psychotropic medica-
tion, remain understudied. In other words, clinicians and
researchers seem to pay more attention to the biological
side of pharmacotherapy than to contextual issues [7].
Patients' expectations about treatment effects may be
influenced by pill size, shape, and color, among other fac-
tors. The often cited study by Buckalew and Coffield
showed that capsules were perceived as stronger than tab-
lets, larger capsules were seen as stronger than smaller
ones, and some capsule colors were specifically ascribed
expectations about drug action [8]. Important inter-ethnic
variations were demonstrated, e.g. Caucasians expected
black capsules to be stimulant, while African-Americans
expected them to be sedative [9]. In the present article, the
term ethno-cultural is used in its broad definition and has
to do with collective identity, i.e. the setting apart of one
group of people from another on the basis of historical
lineage, language, religion and membership of a commu-
nity [10].
Ethno-cultural differences have repeatedly been found
with regard to attribution of causes of various disorders
(e.g. somatic vs. spiritual/divine). These "explanatory
models of illness" are of special importance in mental
health [11]. Eventually, culture influences representa-
tions, compliance, expectations about treatment and
engagement with services [12].
Some psychometric instruments have been developed in
order to analyze subjective parameters of pharmacother-
apy. To our knowledge, these instruments took into con-
sideration ethnic and cultural factors only marginally. For
example, the widely used Drug Attitude Inventory (DAI),
which was translated into several languages since its ini-
tial validation in the eighties, does not investigate ethno-
cultural aspects, neither in its shortened version (DAI-10),
nor in its long version (DAI-30) [13]. Several other instru-
ments exist, but they address exclusively psychotic disor-
ders [14-16]. The aim of the present study was to
contribute filling this gap and analyze cultural factors
influencing attitudes toward psychotropic drug treatment
in a multi-ethnic sample of psychiatric inpatients.
Methods
Setting
The study was conducted in one admission unit of the
public psychiatric hospital in Geneva, an international,
multicultural city of approximately 430'000 inhabitants
located in the French speaking part of Switzerland. During
the study period, the 15 to 18-bed general psychiatry unit
received patients with primary diagnoses of affective dis-
orders (33%), schizophrenia and other psychotic disor-
ders (33%), alcohol and other substance use disorders
(15%), personality disorders (10%) and other disorders
(9%). During the 11-month recruitment period, a total of
400 patients were hospitalized in the unit (mean length of
stay 14.4 days). All patients admitted to this unit and
meeting inclusion criteria were individually approached.
Inclusion criteria were sufficient length of stay to allow for
psychiatric assessment (at least 2 days) and for partial
remission of acute behavioral or psychotic symptoms.
Patients who gave written informed consent were inter-
viewed until 100 participants were recruited. Patients who
did not provide informed consent did not differ clinically
from those who gave consent. The study was approved by
the local ethics committee.
Questionnaire
Taking into account a literature review about cultural con-
siderations in non-biological issues affecting psychophar-
macotherapy [17], we developed an ad hoc observer-
rating questionnaire. Three preliminary versions were pre-
tested, thus permitting to reformulate or eliminate ques-
tions which were too difficult to understand or too vague.
In its final version (available upon request), the question-
naire contained 22 items. Answers were rated on Likert
scales (e.g. "not at all", "not really", "not sure", "rather
yes", and "yes, very much"). For analysis, values were
dichotomized by grouping the 3 former categories and the
2 latter ones, respectively. The following domains were
investigated: personal opinion about drug aspect, admin-
istration mode and information about treatment,
expected drug effects, use of alternative or complementary
medicine and perceived influence of context and general
attitude toward medication. Finally, four questions specif-
ically addressed beliefs among immigrants to Switzerland.
Two experienced clinicians (a psychiatrist and a psycholo-
gist) conducted the interviews. Professional translators
were used for patients who did not speak French, the local
language.
Patients
One hundred hospitalized patients were included in the
study (age range 19–65). Median length of stay was 7 days
(range 2–67). Median number of prescribed drugs at the
moment of the interview was 3 (range 0–10).BMC Psychiatry 2008, 8:55 http://www.biomedcentral.com/1471-244X/8/55
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Patients were pooled into 3 groups according to their
country of origin:
(1) 54 patients originated from Switzerland
(2) 25 patients came from a country that was part of the
European Union (EU) (Italy n = 6, Spain n = 6, Portugal n
= 6, France n = 5, Greece n = 1, UK n = 1)
(3) 21 patients came from non-EU countries (Turkey n =
3, Zaire n = 2, Algeria, Angola, Bosnia, Brazil, Burundi,
Cameroon, Chile, Congo, Morocco, Nigeria, Poland,
Rumania, Rwanda, Senegal, Sudan, USA: n = 1 from each
country). Poland and Rumania were not yet EU members
at the time of the study.
The first group corresponds to patients sharing the local
culture; the second group corresponds to patients that
share some European ethno-cultural characteristics; the
third group is composed of persons with very diverse
ethno-cultural backgrounds.
Among subjects with a non-Swiss origin, 5 (10.9%) were
asylum-seekers, 3 (6.5%) had a non-permanent residence
permit (type B permit, valid for five years), 24 (52.2%)
had a permanent residence permit (type C, with unre-
stricted access to labor market) and 13 (28.3%) had
become Swiss citizens.
Socio-demographic and treatment characteristics of par-
ticipants are reported in Table 1.
Statistical analysis
The Fisher exact test for proportions was used for compar-
isons between groups, with significance level set at 0.05
(2-sided). Data were analyzed using the SPSS program,
version 11 (SPSS Inc., Chicago IL, USA).
Results
Socio-demographic characteristics and current 
pharmacotherapy
As shown in Table 1, the 3 groups significantly differed
with respect to religion, with Catholics over represented
Table 1: Socio-demographic characteristics and current pharmacotherapy
Swiss
(N=54)
European
Union
(N=25)
Others
(N=21)
p
Women 21 38.9% 10 40.0% 6 28.6% 0.67
Age ≥ 40 years 26 48.1% 12 48.0% 4 19.0% 0.06
Religion
Catholic 26 48.1% 19 76.0% 9 42.9% 0.001
Protestant 12 22.2% 0 0.0% 0 0.0%
Jewish 0 0.0% 0 0.0% 0 0.0%
Muslim 4 7.4% 0 0.0% 6 28.6%
Atheist 8 14.8% 4 16.0% 2 9.5%
Other 4 7.4% 2 8.0% 4 19.0%
French skills
Excellent 54 100.0% 22 88.0% 17 81.0% 0.006
Fair 0 0.0% 2 8.0% 2 9.5%
Insufficient 0 0.0% 1 4.0% 2 9.5%
Living status
Living alone 26 48.1% 9 36.0% 11 52.4% 0.74
Couple 12 22.2% 6 24.0% 2 9.5%
Family 11 20.4% 8 32.0% 6 28.6%
Institution 5 9.3% 2 8.0% 2 9.5%
Education (N = 99)
None – elementary 4 7.4% 1 4.0% 0 0.0% 0.46
Compulsory education 12 22.2% 11 44.0% 6 30.0%
Apprenticeship 20 37.0% 6 24.0% 5 25.0%
College 7 13.0% 5 20.0% 4 20.0%
Technical school 6 11.1% 1 4.0% 1 5.0%
University 5 9.3% 1 4.0% 4 20.0%
Current medication (N = 95)
Antipsychotics 28 54.9% 11 47.8% 15 71.4% 0.26
Antidepressants 28 54.9% 13 56.5% 6 28.6% 0.10
Mood stabilizers 21 41.2% 4 17.4% 5 23.8% 0.09
Tranquilizers 18 35.3% 10 43.5% 6 28.6% 0.63
Hypnotics 20 39.2% 5 21.7% 8 38.1% 0.34BMC Psychiatry 2008, 8:55 http://www.biomedcentral.com/1471-244X/8/55
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among patients from the EU, Protestants only represented
among Swiss patients and the largest proportion of Mus-
lims among non-EU subjects. Even though differences
between groups were significant, a large majority of
patients spoke French fluently in all 3 groups (> 80%).
There were no significant differences between groups with
regard to prescribed psychotropic medication.
Patient opinion about drug aspect, formulation and 
information
A majority of patients rated the general aspect of the med-
ication as important or very important. Taste was the spe-
cific aspect most often rated as important, followed by
tablet size, shape, color, and package design. No signifi-
cant difference was observed between patients of different
origins (Table 2).
If they could choose the administration mode of their psy-
chotropic treatment, most patients would prefer to take
the drug orally. Only a minority of patients (< 30%)
would select intravenous, intramuscular or subcutaneous
administration (Table 2).
A large majority of patients (≥ 90%), independently of
their country of origin, would prefer to be informed about
drug therapeutic and adverse effects by their attending
physician. Information by nurses and written patient
information were cited next. Interestingly, Swiss patients
mentioned information from other patients significantly
less often than foreigners (Table 2).
Expected effects of medication and perceived influence of 
ethno-cultural context
Sixty-eight percent of patients expected side effects and
60% thought that adverse effects might be severe enough
to let them stop treatment. Thirty percent expected nega-
tive personal changes with treatment, whereas 62%
expected positive changes. Thirty six percent of the sample
used alternative or complementary medicines. While the
opinion of significant others about treatment was more
frequently cited among patients from foreign countries
than from Switzerland, no difference was found for the
possible interference between religious beliefs and treat-
ment (Table 3).
Patients' attitudes toward medication
Thirty four percent of patients thought that their mental
disorder could have been treated without drugs. Patients
from non-European countries were significantly less often
positive about taking medication than patients from the
other two groups. However, in each group, a large major-
ity of patients (> 90%) reported that they would probably
Table 2: Patients' opinion about drug aspect, formulation and information §
Total 
sample 
(N=92–100)*
Swiss
(N=50–54)*
European 
Union
(N=21–25)*
Others 
(N=20–21)*
p
Are the following aspects of the drug important to you?
General aspect 54.5% 58.5% 44.0% 57.1% 0.53
Taste 56.0% 51.9% 56.0% 66.7% 0.53
Size 46.0% 46.3% 44.0% 47.6% 1.00
Shape 33.0% 37.0% 16.0% 42.9% 0.10
Color 31.0% 31.5% 20.0% 42.9% 0.25
Package design 26.0% 31.5% 8.0% 33.3% 0.047
If possible, would you select the following administration modes?
Tablets 92.9% 90.6% 96.0% 95.2% 0.77
Effervescent tablets 62.6% 61.1% 58.3% 71.4% 0.70
Drops 45.9% 45.3% 50.0% 42.9% 0.89
Intravenous injection 26.5% 22.6% 33.3% 28.6% 0.56
Intramuscular injection 18.4% 18.9% 12.5% 23.8% 0.69
Subcutaneous injection 16.5% 23.1% 12.5% 4.8% 0.15
From which sources do prefer to be informed about drug treatment?
Physician 92.6% 92.2% 95.7% 90.0% 0.88
Nurse 74.2% 74.0% 73.9% 75.0% 1.00
Written patient information 74.2% 80.4% 59.1% 75.0% 0.17
Books, magazines 32.6% 32.0% 31.8% 35.0% 1.00
Family, important others 26.1% 24.0% 27.3% 30.0% 0.86
Television 25.0% 17.6% 28.6% 40.0% 0.12
Other patients 13.0% 4.0% 22.7% 25.0% 0.010
* Missing values excluded from % calculation.
§ Percents refer to patients who answered "yes" or "yes, very much"BMC Psychiatry 2008, 8:55 http://www.biomedcentral.com/1471-244X/8/55
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or certainly continue to take the medication as prescribed
after discharge from the hospital.
When compared with patients from EU-countries, sub-
jects from non-European countries significantly more
often thought that they received medication not available
in their home country. While more than 80% of EU-
patients believed that they would have the same reaction
to medication as Swiss patients, this was the case for only
45% of non-European patients (Table 4).
Discussion
Globalization has led to a significant increase in migra-
tions. People are now moving further, faster and in greater
numbers than ever before [18]. This phenomenon
impacts on psychiatric services. Several studies have
indeed shown that patients consulting in western psychi-
atric facilities are increasingly multiethnic and multicul-
tural [19]. In this context, it is important for caregivers to
be aware of patients' attitudes toward treatments, as a
form of cultural competence [20].
Table 3: Expected effects of medication and perceived influence of ethno-cultural context §
Total
sample
(N=99–100)*
Swiss 
(N=54)
European 
Union 
(N=24–25)*
Others 
(N=21)
p
Do you expect side effects? 68.0% 66.7% 60.0% 81.0% 0.29
Might these side effects be severe enough to let you interrupt the treatment? 60.0% 55.6% 56.0% 76.2% 0.25
Do you expect positive personal changes (character, personality ...) due to 
pharmacotherapy?
62.0% 64.8% 60.0% 57.1% 0.82
Do you expect negative personal changes (character, personality ...) due to 
pharmacotherapy?
30.0% 24.1% 40.0% 33.3% 0.32
Do significant others have an opinion regarding your treatment? 57.6% 46.3% 75.0% 66.7% 0.041
Do you use alternative/complementary medicine (homeopathy, traditional medicine 
etc.)?
36.4% 44.4% 33.3% 19.0% 0.12
Does your physician's attitude influence treatment result? 72.0% 66.7% 72.0% 85.7% 0.28
Does your nurses' attitude influence treatment result? 69.0% 66.7% 60.0% 85.7% 0.14
Do your religious beliefs and practices interfere with treatment? 9.0% 5.6% 16.0% 9.5% 0.32
* Missing values excluded from % calculation.
§ Percents refer to patients who answered "yes" or "yes, very much"
Table 4: Patients' attitudes toward medication §
Total 
sample
(N=99–100)*
Swiss
(N=53–54)*
European 
Union 
(N=17–25)*
Others
(N=17–21)*
p
Do you believe that you could have been treated 
without medication?
34.0% 29.6% 28.0% 52.4% 0.15
Is your self image modified by the medication you 
are taking?
48.5% 43.4% 56.0% 52.4% 0.55
What is your general opinion about taking medications?
(% positive or very positive)
59.0% 68.5% 64.0% 28.6% 0.007
What is your general opinion about taking psychiatric
medications? (% positive or very positive)
44.0% 51.9% 40.0% 28.6% 0.19
Are you going to take your medication as prescribed
after discharge from the hospital? (% probably yes or yes)
94.0% 94.4% 92.0% 95.2% 0.86
Do you consider all medications the same way? 16.0% 16.7% 8.0% 23.8% 0.35
Do you receive a treatment that you could not get in 
your country of origin?
17.6% 58.8% 0.032
Could you receive, in your country of origin, 
a treatment you do not get here?
13.0% 31.6% 0.26
Do you think you get the same treatment as a Swiss
patient?
78.3% 90.0% 0.42
Do you think you have the same reaction to 
medication as a Swiss patient?
82.6% 45.0% 0.013
* Missing values excluded from % calculation.
§ Percents refer to patients who answered "yes" or "yes, very much", unless indicated otherwiseBMC Psychiatry 2008, 8:55 http://www.biomedcentral.com/1471-244X/8/55
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To our knowledge, the present study is the first European
survey examining differences of attitudes and beliefs
toward psycho-pharmacotherapy in psychiatric patients
from various ethno-cultural backgrounds. Our study con-
firms the importance given by patients to external charac-
teristics of drugs, like taste and tablet size, and their
preference for oral administration. There were few inter-
cultural differences in this respect.
Physicians were clearly the preferred information source
for the whole sample. Foreign patients tended to rely
more on other patients on the ward as a source of infor-
mation, compared with Swiss subjects. One possible
explanation is that Swiss patients are more familiar with
the local medical system and therefore accept therapeutic
procedures more easily than foreign patients, the latter
needing reassurance from experienced persons outside the
medical staff. It could also be caused by insufficient or
inadequate medical information given to foreign patients.
The appropriate transmission of medical information is
dependent on communication between staff and patient.
Both profound cultural differences and insufficient use of
trained interpreters can impede such communication in
our local setting [21].
The opinion of relatives about treatment was cited more
frequently by foreign patients than local patients. This
could be due to differences regarding familial cohesion,
which can be considered as traditionally stronger in
Southern and Eastern countries than in Western Europe or
the US. Indeed, migrants included in this study moved
from collectivist (or socio-centric) societies to an individ-
ualistic (or ego-centric) one [22]. This finding could also
reflect an increased need for peer support among people
living in a foreign country.
The general opinion of non-European patients about tak-
ing medications was less often positive than among the
European sub-groups. This result might reflect differences
in diagnoses and/or cultural representations: Western
medicines may be subject to different beliefs by different
cultural groups, affecting their attitudes toward them [23].
Strikingly, more than 90% of all participants declared that
they intended to take their medication as prescribed after
discharge from the hospital. This result contrasts with
adherence rates usually reported in the literature: rates of
adherence for psychiatric illnesses are seldom above 65%
and sometimes as low as 35% [24]. Our result could
reflect social desirability and willingness to appear adher-
ent to treatment.
This study has several limitations. Firstly, country of ori-
gin was used as a proxy for ethno-cultural background.
Place of birth and language spoken at home are more
commonly accepted indicators [25]. However, since
obtaining the Swiss nationality is a long and complicated
process, we believe that most immigrants included in the
study would have retained their nationality of origin. Sec-
ondly, attitudes toward medication were investigated
from the patient's perspective only. It is however well
known that patterns of prescription also vary with physi-
cians' cultural stereotypes [26]. In the present study,
although not statistically significant, non-European
patients tended to receive more often antipsychotic medi-
cations and less often antidepressants than Swiss and
European patients (p = 0.26 and 0.10 respectively).
Whereas these different prescription patterns might be
associated with different distribution of diagnoses across
groups, a cultural bias could also be invoked. Thirdly,
other cultural factors that may influence preferences and
attitudes toward treatment, such as spirituality, stigma or
access to care [27], were not investigated. Fourthly, diag-
noses were not recorded. However, we found no signifi-
cant differences between patients treated with or without
antipsychotic medication. This observation indicates that
patients with a diagnosis of psychotic disorder, i.e.
approximately one third of the sample, did not differ from
patients with other diagnoses regarding attitudes toward
medication. Fifthly, due to the absence of appropriate
instruments in the literature, we used a non-validated
questionnaire designed purposely for the study. Finally,
the sample was too small to demonstrate subtle differ-
ences between the 3 different cultural groups.
Conclusion
Patients treated in a Swiss psychiatric hospital share most
of their pharmacotherapy related attitudes and expecta-
tions independently of their region of origin. Medical staff
members are the most trusted sources of information.
However, there are some important differences between
local and foreign patients. Results speak in favor of better
integrating relatives of non-European patients in the ther-
apeutic process. Sharing experiences, beliefs and expecta-
tions regarding treatment with other patients also appear
to be of a special importance for foreign subjects. In order
to improve adherence with treatment, these observations
should be taken into account when organizing clinical
services that serve culturally diverse populations.
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